MedPath

BREO ELLIPTA

BREO ELLIPTA

Approved
DIN Number

02444186

Drug Class

Human

Market Date

Oct 2, 2015

Company
HC

GlaxoSmithKline Inc

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02444186
AIG Number0254450004
Classification & Schedule
C
Drug Class
Human
S
Schedule
Prescription
A
ATC Code
R03AK10 VILANTEROL AND FLUTICASONE FUROATE
Product Specifications
Dosage FormPowder
Route of AdministrationInhalation
AHFS Classification68:04.00
Health Canada Classification

ACTIVE INGREDIENTS (2)

FLUTICASONE FUROATEActive
Strength: 200 MCG / ACT
Monograph: FLUTICASONE FUROATE
VILANTEROL (VILANTEROL TRIFENATATE)Active
Strength: 25 MCG / ACT
Monograph: VILANTEROL (VILANTEROL TRIFENATATE)

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.